Down 25% with a 4.32% yield and P/E of 8.6! Is this my best second income stock or worst?

Harvey Jones bought GSK shares hoping to bag a solid second income stream while nailing down steady share price growth as well. Sadly, it hasn’t turned out that way.

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I really don’t know what to make of this hugely popular FTSE 100 second income stock. I don’t know if it’s a brilliant British blue-chip having a bad run, or a bad blue-chip that’s getting what it deserves.

The one thing I know for sure is that the GSK (LSE: GSK) share price hasn’t performed how I expected when I bought the pharmaceutical stock at the start of this year.

And now I’m asking myself three questions. Should I take advantage of its recent troubles to buy more?Should I sell and move on? Or hold and hope for the best?

The GSK share price is a nightmare

I have distant memories of the days when – in its former incarnation as GlaxoSmithKline – this was every income seeker’s favourite UK stock. At least, that’s how it felt at the time.

Investors bought it for its solid yield, which typically hovered around the 5% to 6% mark, and the happy expectation of share price growth on top. Then gradually, they began to worry about the drugs pipeline, that was looking a bit thin as former blockbuster treatments went off patent, and new ones were slow to arrive.

CEO Emma Walmsley, appointed in 2017, set to work putting that right but had to sacrifice dividend growth to do it. With shareholder payouts frozen at 80p per share and the stock refusing to rally as hoped, investors drifted away.

Hiving off consumer arm Haleon in 2022 didn’t bring back them back. I thought GSK looked good value in January and dived in. There were more problems just around the corner.

A decent dividend yield at a bargain price

My shares slumped over the summer when a US class action claimed that a discontinued version of its blockbuster heartburn treatment Zantac caused cancer. The shares rallied when most claims were settled in a $2.2bn payout on 9 October.

But within a month they were crashing as Donald Trump won the US presidency and appointed controversial vaccine sceptic Robert F Kennedy, Jr, as US Health Secretary. Trump is taking on big pharma.

The GSK share price is now down 24.6% in the last six bumpy months, although it’s still up 5.95% over the last year. It looks terrific value though, trading at just 8.63 times earnings. In the old days, it was routinely valued at 15 times.

Plus the previously underwhelming yield has jumped to 4.63%. So to my three questions. Should I buy more? Answer: no. There’s now a big question mark over the sector while we wait to see what Kennedy does. Gambling on buying more would be a blind bet.

Should I sell? I’m sitting on a 20% loss and I’m not too happy about crystallising that. A lot of bad news has been priced in, and maybe things won’t be as bad as they look.

Which brings me to the final question and yes, I’ll hold. Investing is a long-term game and things may get better at GSK. Although being honest, I wish I’d never bought it at all. There are better passive income stocks out there.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has positions in GSK. The Motley Fool UK has recommended GSK and Haleon Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Dividend Shares

3 simple passive income investment ideas to consider for 2025

It’s never been easier to generate passive income from the stock market. Here are three straightforward investment strategies to consider…

Read more »

Investing Articles

I was wrong about the IAG share price last year. Should I buy it in 2025?

The IAG share price soared in 2024 and analysts are expecting more of the same in 2025. So should Stephen…

Read more »

Investing Articles

Here’s the dividend forecast for National Grid shares through to 2027

After a volatile 12 months, National Grid shares are expected to provide a dividend yield of 4.8% for the company’s…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Growth Shares

2 exceptional growth funds that beat Scottish Mortgage shares in 2024

Scottish Mortgage shares generated double-digit returns for investors in 2024. But these two growth-focused investment funds did much better.

Read more »

Investing Articles

If a 40-year-old put £500 a month in S&P 500 shares, here’s what they could have by retirement

A regular investment in S&P 500 shares could help a middle-aged person build a million-pound portfolio. Royston Wild explains.

Read more »

New year resolutions 2025 on desk. 2025 resolutions list with notebook, coffee cup on table.
Investing Articles

Buying more Greggs shares is top of my New Year’s resolutions!

Looking for top growth shares to consider in 2025? Here's why Greggs shares are at the top of my shopping…

Read more »

Investing Articles

Could Rigetti Computing be a millionaire-maker growth stock at $17?

Rigetti Computing (NASDAQ:RGTI) is up 470% in just the past month! Should I rush out to buy this quantum computing…

Read more »

Investing Articles

Want to double your money by 2030? Here are 3 ETFs to consider in January!

These UK-based exchange-traded funds (ETFs) could help investors get 2025 off to a bang! Our writer Royston Wild explains why.

Read more »